Long-term treatment of cancer pain with transdermal fentanyl

Journal of Pain and Symptom Management

Volumn 15, Issue 3, 1998, Pages 168-175

  Donner, Barbara ^a   Zenz, Michael ^a   Strumpf, Michael ^a   Raber, Manfred ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Cancer pain; Constipation; Long term therapy; Side effects; Transdermal fentanyl

Indexed keywords

FENTANYL; LAXATIVE; MORPHINE;

ADULT; AGED; ANALGESIA; ARTICLE; CANCER PAIN; CLINICAL TRIAL; COLON CARCINOMA; CONSTIPATION; DOSE RESPONSE; ERYTHEMA; FEMALE; HUMAN; LONG TERM CARE; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PAPULE; PRACTICE GUIDELINE; PRURITUS; PUSTULE; SKIN EDEMA; SUSTAINED RELEASE PREPARATION; TRANSDERMAL DRUG ADMINISTRATION; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; ANALGESICS, OPIOID; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN; TIME FACTORS;

EID: 0031961652     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(97)00361-8     Document Type: Article

References (26)

1. Herbst L.H., Strause L.G. Transdermal fentanyl use in hospice home-care patients with chronic cancer pain. J Pain Symptom Manage. 7(suppl):1992;54-57.
2. Levy M.H., Rosen S.M., Kedziera P. Transdermal fentanyl. seeding trial in patients with chronic cancer pain J Pain Symptom Manage. 7(suppl):1992;48-50.
3. Maves T.J., Barcellos W.A. Management of cancer pain with transdermal fentanyl. Phase IV trial, University of Iowa J Pain Symptom Manage. 7(suppl):1992;58-62.
4. Miser A.W., Narang P.K., Dothage J.A., Young R.C., Sindelar S., Miser J.S. Transdermal fentanyl for pain control in patients with cancer. Pain. 37:1989;15-21.
5. Patt R.B., Hogan L.A. Transdermal fentanyl for chronic cancer pain. detailed case reports and the influence of confounding factors J Pain Symptom Manage. 7(suppl):1992;51-53.
6. Simmonds M.A., Payne R., Richenbacher J., Moran K., Southam M.A., Hershe M.S. TTS (fentanyl) in the management of pain in patients with cancer [abst]. Proc Am Soc Clin Oncol. 8:1989;324.
7. Zech D., Lehmann K.A. Transdermal fentanyl in combination with initial intravenous dose titration by patient controlled analgesia. Anticancer Drugs. 6(suppl 3):1995;44-49.
8. Zech D., Grond S., Dauer H.G., Stollenwerk B., Lehmann K.A. Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain. a pilot study with 20 terminally ill cancer patients Pain. 50:1992;293-301.
9. Donner B., Zenz M., Tryba M., Strumpf M. Transdermal fentanyl in cancer pain. conversion from sustained release morphine to fentanyl TTS - a multicenter study Pain. 64:1996;527-534.
10. Portenoy R.K., Southam M., Gupta S.K.et al. Transdermal fentanyl for cancer pain. repeated dose pharmacokinetics Anesthesiology. 78:1993;36-43.
11. Simmonds M.A. Transdermal fentanyl therapy. clinical development in the United States Anticancer Drugs. 6(suppl 3):1995;35-38.
12. World Health Organization Cancer pain relief. 1986;World Health Organization, Geneva.
13. Zenz M., Piepenbrock S., Tryba M., Glocke M., Everlien M., Klauke W. Langzeittherapie von Krebsschmerzen - kontrollierte Studie mit Buprenorphin. Dtsch Med Wochenschr. 110:1985;448-453.
14. Zenz M., Strumpf M., Tryba M., Röhrs E., Steffmann B. Retardiertes Morphin zur Langzeittherapie schwerer Tumorschmerzen. Dtsch Med Wochenschr. 114:1989;43-47.
15. Calis K.A., Kohler D.R., Corso D.M. Transdermally administered fentanyl for pain management. Clin Pharmacy. 11:1992;22-36.
16. Janssen Pharmaceutica Inc. Product monograph "Duragesic," fentanyl transdermal system. Mississauga, Ontario, Canada, 1991.
17. Payne R., Chandler S., Einhaus M. Guidelines for the clinical use of transdermal fentanyl. Anticancer Drugs. 6(suppl 3):1995;50-53.
18. Gourlay G.K., Kowalski S.R., Plummer J.L., Cherry D.A., Gaukroger P., Cousins M.J. The transdermal administration of fentanyl in the treatment of postoperative pain. pharmacokinetics and pharmacodynamic effects Pain. 37:1989;193-202.
19. Ahmedzai S., Alan E., Fallon M.et al. Transdermal fentanyl in cancer pain. J Drug Dev. 6:1994;93-97.
20. Korte W., Morant R. Transdermal fentanyl in uncontrolled cancer pain. titration on day-to-day basis as a procedure for safe and effective dose finding - a pilot study in 20 patients Support Care Cancer. 2:1994;123-127.
21. Simmonds M.A. Transdermal fentanyl therapy. clinical development in the United States Anticancer Drugs. 6(suppl 3):1995;35-38.
22. Levy S., Jacobs S., Johnson J.et al. Transdermal fentanyl. pain and quality-of-life effects Proc Am Soc Clin Pharm. 7:1988;292.
23. Jurna I., Baldauf J. Retardiert freigesetztes Naloxon oral. aufhebung der obstipation durch orales orphin ohne Beseitigung der Analgesie Der Schmerz. 7:1993;314-321.
24. Stoukides C., Stegman M. Diffuse rash associated with transdermal fentanyl. Clin Pharm. 11:1992;222.
25. Slover R. Transdermal fentanyl. clinical trial at the University of Colorado Health Science Center Pain Symptom Manage. 7(suppl):1992;45-47.
26. Willweber-Strumpf A., Zenz M., Tryba M. Leitlinien zur Therapie chronischer Schmerzen mit Opioiden. Ergebnisse des Sertürner Workshops "Chronische Opioidtherapie." Anaesthesist. 44:1995;719-723.